Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1984 May;49(5):571–577. doi: 10.1038/bjc.1984.91

Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.

G E Adams, I Ahmed, P W Sheldon, I J Stratford
PMCID: PMC1976714  PMID: 6547051

Abstract

Electron affinity as measured by the one-electron reduction potential, E17, is the major factor influencing radiosensitizing efficiency in vitro. RSU 1069 has an electron affinity (E17 = -398 mV) similar to misonidazole; however, the ability of this compound to sensitize hypoxic cells is considerably greater than that of misonidazole, e.g. 0.2 mM RSU 1069 gives an enhancement ratio of 2.2 compared to 1.5 for the same concentration of misonidazole. Radiosensitization studies with the MT tumour in vivo also showed RSU 1069 to be a more efficient sensitizer than misonidazole. An administered dose of only 0.08 mg g-1 RSU 1069 yielded an enhancement of 1.8 to 1.9 using tumour cell survival and tumour cure as end-points. The ability of RSU 1069 to potentiate the cytotoxic action of melphalan towards the MT tumour was also examined. RSU 1069 (0.08 mg g-1) given to mice 1 h before melphalan resulted in an enhancement of 3.0. In contrast, previous studies had shown with a series of nitroimidazoles including misonidazole that Ro 03-8799 was the most effective potentiating agent, but this only gave an enhancement of 2.3 at a 10-fold higher dose than RSU 1069. RSU 1069 is a compound of substantial promise both as a radiosensitizer and chemopotentiating agent and warrants further investigation.

Full text

PDF
576

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Ahmed I., Clarke E. D., O'Neill P., Parrick J., Stratford I. J., Wallace R. G., Wardman P., Watts M. E. Structure-activity relationships in the development of hypoxic cell radiosensitizers. III. Effects of basic substituents in nitroimidazole sidechains. Int J Radiat Biol Relat Stud Phys Chem Med. 1980 Dec;38(6):613–626. doi: 10.1080/09553008014551451. [DOI] [PubMed] [Google Scholar]
  2. Adams G. E., Clarke E. D., Flockhart I. R., Jacobs R. S., Sehmi D. S., Stratford I. J., Wardman P., Watts M. E., Parrick J., Wallace R. G. Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. Int J Radiat Biol Relat Stud Phys Chem Med. 1979 Feb;35(2):133–150. doi: 10.1080/09553007914550151. [DOI] [PubMed] [Google Scholar]
  3. Adams G. E., Clarke E. D., Gray P., Jacobs R. S., Stratford I. J., Wardman P., Watts M. E., Parrick J., Wallace R. G., Smithen C. E. Structure-activity relationships in the development of hypoxic cell radiosensitizers. II. Cytotoxicity and therapeutic ratio. Int J Radiat Biol Relat Stud Phys Chem Med. 1979 Feb;35(2):151–160. doi: 10.1080/09553007914550161. [DOI] [PubMed] [Google Scholar]
  4. Adams G. E., Flockhart I. R., Smithen C. E., Stratford I. J., Wardman P., Watts M. E. Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res. 1976 Jul;67(1):9–20. [PubMed] [Google Scholar]
  5. Adams G. E., Stratford I. J., Wallace R. G., Wardman P., Watts M. E. Toxicity of nitro compounds toward hypoxic mammalian cells in vitro: dependence on reduction potential. J Natl Cancer Inst. 1980 Mar;64(3):555–560. [PubMed] [Google Scholar]
  6. Beaman A. G., Tautz W., Duschinsky R. Studies in the nitroimidazole series. 3. 2-Nitroimidazole derivatives substituted in the 1-position. Antimicrob Agents Chemother (Bethesda) 1967;7:520–530. [PubMed] [Google Scholar]
  7. Brown J. M., Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res. 1980 Apr;82(1):171–190. [PubMed] [Google Scholar]
  8. Brown J. M., Yu N. Y., Brown D. M., Lee W. W. SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys. 1981 Jun;7(6):695–703. doi: 10.1016/0360-3016(81)90460-0. [DOI] [PubMed] [Google Scholar]
  9. Brown J. M., Yu N. Y. The optimum time for irradiation relative to tumour concentration of hypoxic cell sensitizers. Br J Radiol. 1980 Sep;53(633):915–916. doi: 10.1259/0007-1285-53-633-915. [DOI] [PubMed] [Google Scholar]
  10. Clement J. J., Gorman M. S., Wodinsky I., Catane R., Johnson R. K. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res. 1980 Nov;40(11):4165–4172. [PubMed] [Google Scholar]
  11. Cobb L. M., Connors T. A., Elson L. A., Khan A. H., Mitchley B. C., Ross W. C., Whisson M. E. 2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem Pharmacol. 1969 Jun;18(6):1519–1527. doi: 10.1016/0006-2952(69)90267-6. [DOI] [PubMed] [Google Scholar]
  12. Connors T. A., Mandel H. G., Melzack D. H. Studies on the reversal of the selective antitumour effect of the aziridinyl derivative CB 1954 by 4-amino-5-imidazolecarboxamide. Int J Cancer. 1972 Jan 15;9(1):126–132. doi: 10.1002/ijc.2910090115. [DOI] [PubMed] [Google Scholar]
  13. Connors T. A., Melzack D. H. Studies on the mechanism of action of 5-aziridinyl-2,4-dinitrobenzamide (CB 1954), a selective inhibitor of the Walker tumour. Int J Cancer. 1971 Jan 15;7(1):86–92. doi: 10.1002/ijc.2910070110. [DOI] [PubMed] [Google Scholar]
  14. Dische S., Fowler J. F., Saunders M. I., Stratford M. R., Anderson P., Minchinton A. I., Lee M. E. A drug for improved radiosensitization in radiotherapy. Br J Cancer. 1980 Jul;42(1):153–155. doi: 10.1038/bjc.1980.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hickman J. A., Melzack D. H. Protection against the effects of the antitumour agent CB 1954 by certain imidazoles and related compounds. Biochem Pharmacol. 1975 Nov 1;24(21):1947–1952. doi: 10.1016/0006-2952(75)90380-9. [DOI] [PubMed] [Google Scholar]
  16. Law M. P., Hirst D. G., Brown J. M. Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide. Br J Cancer. 1981 Aug;44(2):208–218. doi: 10.1038/bjc.1981.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Martin W. M., McNally N. J., De Ronde J. Enhancement of the effect of cytotoxic drugs by radiosensitizers. Br J Cancer. 1981 Jun;43(6):756–766. doi: 10.1038/bjc.1981.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. McNally N. J., Denekamp J., Sheldon P., Flockhart I. R., Stewart F. A. Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer. Radiat Res. 1978 Mar;73(3):568–580. [PubMed] [Google Scholar]
  19. Mulcahy R. T., Siemann D. W., Sutherland R. M. In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU. Br J Cancer. 1981 Jan;43(1):93–99. doi: 10.1038/bjc.1981.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Saunders M. I., Dische S., Fermont D., Bishop A., Lenox-Smith I., Allen J. G., Malcolm S. L. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study. Br J Cancer. 1982 Nov;46(5):706–710. doi: 10.1038/bjc.1982.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sheldon P. W., Batten E. L., Adams G. E. Potentiation of melphalan activity against a murine tumour by nitroimidazole compounds. Br J Cancer. 1982 Oct;46(4):525–531. doi: 10.1038/bjc.1982.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sheldon P. W., Hill S. A. Further investigations of the effects of the hypoxic-cell radiosensitizer, Ro-07-0582, on local control of a mouse tumour. Br J Cancer. 1977 Aug;36(2):198–205. doi: 10.1038/bjc.1977.178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sheldon P. W., Hill S. A. Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumour in mice. Br J Cancer. 1977 Jun;35(6):795–808. doi: 10.1038/bjc.1977.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Siemann D. W. In vivo combination of misonidazole and the chemotherapeutic agent CCNU. Br J Cancer. 1981 Mar;43(3):367–377. doi: 10.1038/bjc.1981.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stephens T. C., Courtenay V. D., Mills J., Peacock J. H., Rose C. M., Spooner D. Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole. Br J Cancer. 1981 Apr;43(4):451–457. doi: 10.1038/bjc.1981.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stephens T. C., Peacock J. H., Sheldon P. W. Influence of in vitro assay conditions on the assessment of radiobiological parameters of the MT tumour. Br J Radiol. 1980 Dec;53(636):1182–1187. doi: 10.1259/0007-1285-53-636-1182. [DOI] [PubMed] [Google Scholar]
  27. Stratford I. J. Mechanisms of hypoxic cell radiosensitization and the development of new sensitizers. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):391–398. doi: 10.1016/0360-3016(82)90646-0. [DOI] [PubMed] [Google Scholar]
  28. Stratford I. J., Williamson C., Hoe S., Adams G. E. Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide). Radiat Res. 1981 Dec;88(3):502–509. [PubMed] [Google Scholar]
  29. Tannock I. F. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. Br J Cancer. 1980 Dec;42(6):871–880. doi: 10.1038/bjc.1980.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tannock I. F. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin. Br J Cancer. 1980 Dec;42(6):861–870. doi: 10.1038/bjc.1980.334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Twentyman P. R. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721. Br J Cancer. 1981 Jun;43(6):745–755. doi: 10.1038/bjc.1981.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Williams M. V., Denekamp J., Minchinton A. I., Stratford M. R. In vivo assessment of basic 2-nitroimidazole radiosensitizers. Br J Cancer. 1982 Jul;46(1):127–137. doi: 10.1038/bjc.1982.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Workman P., Twentyman P. R. Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationships. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):623–626. doi: 10.1016/0360-3016(82)90698-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES